Eye protection instrument based on light response

Abstract

The invention relates to an eye protection instrument based on light response, and belongs to the technical field of medical instruments, the eye protection instrument based on light response comprises a cavity, and a light driving assembly and a medicine carrying assembly which are arranged in the cavity; the light driving assembly comprises an ultraviolet lamp and an infrared lamp which are oppositely arranged up and down in the cavity, and a light response material arranged between the ultraviolet lamp and the infrared lamp; the light response material comprises an ultraviolet light response layer, a flexible middle layer and an infrared light response layer which are sequentially arranged from top to bottom; the medicine carrying assembly is connected with the photoresponse material through the pushing part; the end, connected with the photoresponse material, of the pushing part is lower than the end, connected with the medicine carrying assembly, of the pushing part. The medicine carrying assembly comprises a medicine storage cavity and a medicine carrying microneedle which is arranged on the side wall of the medicine storage cavity and communicates with the medicine storage cavity. According to the eye protection instrument, medicine can be accurately injected into acupuncture points around eyes, and the problems that medicine administration is unstable, the medicine administration efficiency is low, skin is prone to being damaged and the like when medicine is applied to asthenopia at present can be effectively solved.

Description

Technical Field

[0001] The present invention relates to the technical field of medical devices, and in particular to an eye protection device based on light response. Background Art

[0002] Visual fatigue is a common ophthalmic disease in modern society, among which students and computer workers account for a large proportion. Patients with visual fatigue often experience symptoms such as intolerance to long-term vision, blurred vision for a short period of time, dry eyes, burning, itchy eyes, swollen eyes, and tears. In severe cases, they may even suffer from headaches, dizziness, memory loss, and insomnia, which affect normal daily work. Chinese medicine taken orally usually has an irritating effect on the stomach and intestines, and has low bioavailability. Although ordinary patches can make the drug act directly on the local part of the eye, the effective amount of drug absorbed locally cannot be guaranteed, and the absorbed amount of drug is unstable. Eye patches are more common in daily life. They are convenient and have the advantages of local targeting, so they are widely loved by people. However, they are protected by the stratum corneum of the skin, and the drug is not easy to enter. The drug administration is unstable, and it is easy to cause damage to the skin, and the treatment efficiency is not high. Summary of the invention

[0003] In response to one or more technical problems existing in the prior art, the present invention provides an eye protector based on light response. The eye protector provided by the present invention promotes drug-loaded microneedles to deliver drugs through light driving. Under light driving, the drug-loaded microneedles pierce the stratum corneum to form microporous channels, and deliver the active substances to the active epidermis or dermis, thereby greatly improving the absorption of active substances and effectively improving the problem of low transdermal drug delivery efficiency. At the same time, it can minimize skin damage, enhance the delivery of transdermal drugs, effectively avoid the irritation of drugs to the gastrointestinal tract, and improve bioavailability. It can effectively solve the problems of unstable drug delivery, low drug delivery efficiency, low drug utilization rate, and easy damage to the skin during the existing use of drugs for visual fatigue.

[0004] The present invention provides an eye protector based on light response, the eye protector comprises a cavity and a light driving component and a drug carrying component arranged inside the cavity;

[0005] The optical drive assembly includes an ultraviolet lamp and an infrared lamp arranged in the cavity in an upper and lower relative manner and a light responsive material arranged between the ultraviolet lamp and the infrared lamp;

[0006] The light-responsive material comprises an ultraviolet light-responsive layer, a flexible intermediate layer and an infrared light-responsive layer arranged in sequence from top to bottom; the ultraviolet light-responsive layer shrinks toward the light side under ultraviolet light irradiation and then bends toward the backlight side; the infrared light-responsive layer shrinks toward the light side under infrared light irradiation and then bends toward the backlight side;

[0007] The drug-carrying component is connected to the light-responsive material via a pushing component; one end of the pushing component connected to the light-responsive material is lower than one end of the pushing component connected to the drug-carrying component; the drug-carrying component includes a drug storage cavity and a drug-carrying microneedle disposed on a side wall of the drug storage cavity and communicating with the drug storage cavity.

[0008] Preferably, the cavity is provided with a cavity cover; and / or

[0009] The cavity is provided with a fixing component for fixing the eye protector.

[0010] Preferably, an infrared lamp is provided inside the cavity cover for sterilizing and disinfecting the drug carrying assembly.

[0011] Preferably, the thickness ratio of the ultraviolet light response layer, the flexible intermediate layer and the infrared light response layer is 5:3 to 5:7.

[0012] Preferably, the ultraviolet responsive material used in the ultraviolet responsive layer is obtained by chain extension reaction and curing of a mixed system comprising polycaprolactone diol, glycerol, azobenzene-4,4′-dicarboxylic acid and a solvent under the action of an initiator and a catalyst; preferably, azobenzene-4,4′-dicarboxylic acid accounts for 3 to 7 wt % in the ultraviolet responsive layer.

[0013] Preferably, the infrared light response material used in the infrared light response layer is obtained by chain extension reaction and curing of a mixed system containing polycaprolactone diol, glycerol and carbon black under the action of an initiator and a catalyst; preferably, the carbon black in the infrared light response layer accounts for 0.1 to 1 wt%.

[0014] Preferably, the temperature of the chain extension reaction is 58-63°C; and / or

[0015] The curing temperature is 75-80° C. and the curing time is 17-19 hours.

[0016] Preferably, the flexible material used for the flexible intermediate layer is one of porous silica gel and porous rubber; and / or

[0017] The drug-carrying component is a hydrogel material.

[0018] Preferably, the preparation method of the hydrogel material comprises: mixing glycine and an alkaline solution, adding an acryloyl chloride solution, reacting, removing the solvent, alkali dissolving, acid precipitation, and extracting to obtain a polymerized monomer;

[0019] The polymerizable monomer, tannic acid, nano-hydroxyapatite, iron salt and photoinitiator are mixed and subjected to a photocuring reaction to obtain a hydrogel material; preferably, the mass ratio of the iron salt to the tannic acid is 1:10-100.

[0020] Preferably, the photocuring reaction is performed by irradiating ultraviolet light for 9 to 11 minutes.

[0021] Compared with the prior art, the present invention has at least the following beneficial effects:

[0022] The eye protection device provided by the present invention utilizes the vertical deformation ability of the light-responsive material under the irradiation of ultraviolet light and infrared light, and converts the vertical deformation of the light-responsive material into the horizontal movement of the drug-carrying component under the action of the pushing component, so as to realize the smooth and accurate pushing of the drug-carrying component to the acupuncture points around the eye. When taking the medicine, turn on the infrared lamp in the light-driven component, the infrared response layer shrinks toward the light side, and then drives the three-layer light-responsive material to bend upward, and pushes the drug-carrying component toward the human eye through the pushing component, and the drug-carrying microneedle is inserted, and the drug is accurately injected into the acupuncture points around the eye through the penetration effect, so as to achieve the purpose of eye protection. After the medication is finished, turn off the infrared light in the light-driven component, turn on the ultraviolet light, and the ultraviolet response layer shrinks toward the light side, and then drives the three-layer light-responsive material to bend downward, and drives the drug-carrying component away from the human eye through the pushing component.

[0023] The eye protector provided by the present invention drives the drug-loaded microneedles to deliver drugs through light-driven means. The drug-loaded microneedles pierce the stratum corneum to form microporous channels under light-driven means, and deliver the active substances to the active epidermis or dermis, thereby greatly improving the absorption of the active substances and effectively improving the problem of low efficiency of transdermal drug delivery. At the same time, it can minimize skin damage, enhance the delivery of transdermal drugs, and accurately inject drugs into the acupuncture points around the eyes. It is a new type of drug delivery method that is efficient, convenient, controllable, and safe. It can not only effectively avoid the irritation of drugs to the gastrointestinal tract, but also improve bioavailability. It can effectively solve the problems of unstable drug delivery, low drug delivery efficiency, low drug utilization rate, and easy damage to the skin during the existing use of drugs for visual fatigue. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0025] Figure 1 is a schematic structural diagram of an eye protection device based on light response provided by an embodiment of the present invention;

[0026] Figure 2 is a cross-sectional view of an eye protector based on light response provided by an embodiment of the present invention;

[0027] Figure 3 is a schematic structural diagram of a light-responsive material provided by an embodiment of the present invention;

[0028] Figure 4 is a schematic diagram of the connection between the photoresponsive material and the drug-carrying component provided by one embodiment of the present invention;

[0029] Figure 5 This is a distribution diagram of drug-loaded microneedles in a light-responsive eye protection device provided by an embodiment of the present invention;

[0030] Figure 6 It is a schematic structural diagram of a drug-loaded microneedle in a light-responsive eye protection device provided by an embodiment of the present invention;

[0031] Figure 7 It is a schematic structural diagram of a cavity cover in an eye protector based on light response provided in one embodiment of the present invention.

[0032] Reference numerals:

[0033] 1-cavity; 11-ultraviolet lamp; 12-infrared lamp; 13-light-responsive material; 131-ultraviolet light-responsive layer; 132-flexible middle layer; 133-infrared light-responsive layer; 14-pushing component; 15-drug storage cavity; 16-drug-loaded microneedle; 17-drug inlet; 18-cavity cover; 19-fixing component. DETAILED DESCRIPTION

[0034] In order to make the purpose, technical solutions and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative work are within the scope of protection of the present invention.

[0035] The present invention provides an eye protector based on light response, the eye protector comprises a cavity 1 and a light driving component and a drug carrying component arranged inside the cavity;

[0036] The optical drive assembly includes an ultraviolet lamp 11 and an infrared lamp 12 which are arranged in the cavity in an upper and lower relative manner and a light responsive material 13 which is arranged between the ultraviolet lamp 11 and the infrared lamp 12;

[0037] The light-responsive material 13 includes an ultraviolet light-responsive layer 131, a flexible intermediate layer 132, and an infrared light-responsive layer 133, which are sequentially arranged from top to bottom; the ultraviolet light-responsive layer 131 shrinks toward the light side under ultraviolet light irradiation, and then bends toward the backlight side; the infrared light-responsive layer 133 shrinks toward the light side under infrared light irradiation, and then bends toward the backlight side;

[0038] The drug-carrying component is connected to the light-responsive material 13 via a pushing component 14; one end of the pushing component 14 connected to the light-responsive material 13 is lower than one end of the pushing component 14 connected to the drug-carrying component; the drug-carrying component includes a drug storage cavity 15 and a drug-carrying microneedle 16 disposed on the side wall of the drug storage cavity 15 and communicating with the drug storage cavity 15.

[0039] The eye protection device provided by the present invention utilizes the vertical deformation ability of the light-responsive material under the irradiation of ultraviolet light and infrared light, and converts the vertical deformation of the light-responsive material into the horizontal movement of the drug-carrying component under the action of the pushing component, so as to realize the smooth and accurate pushing of the drug-carrying component to the acupuncture points around the eye. When taking the medicine, turn on the infrared lamp in the light-driven component, the infrared response layer shrinks toward the light side, and then drives the three-layer light-responsive material to bend upward, and pushes the drug-carrying component toward the human eye through the pushing component, and the drug-carrying microneedle is inserted, and the drug is accurately injected into the acupuncture points around the eye through the penetration effect, so as to achieve the purpose of eye protection. After the medication is finished, turn off the infrared light in the light-driven component, turn on the ultraviolet light, and the ultraviolet response layer shrinks toward the light side, and then drives the three-layer light-responsive material to bend downward, and drives the drug-carrying component away from the human eye through the pushing component.

[0040] The eye protector provided by the present invention promotes drug-loaded microneedles to deliver drugs through light-driven means. The drug-loaded microneedles pierce the stratum corneum to form microporous channels under light-driven means, and deliver the active substances to the active epidermis or dermis, thereby greatly improving the absorption of the active substances and effectively improving the problem of low efficiency of transdermal drug delivery. At the same time, it can minimize skin damage and enhance the delivery of transdermal drugs. It is a new type of drug delivery method that is efficient, convenient, controllable and safe. It can not only effectively avoid the irritation of drugs to the gastrointestinal tract, but also improve bioavailability. It can effectively solve the problems of unstable drug delivery, low drug delivery efficiency, low drug utilization rate, easy damage to the skin, etc. during the existing use of drugs for visual fatigue.

[0041] In some preferred embodiments of the present invention, when the photoresponsive material is irradiated with infrared red light and has the maximum deformation, the height of the connecting end of the pushing component and the photoresponsive material is consistent with the height of the connecting end of the pushing component and the drug-carrying component, that is, the length of the pushing component when it is horizontal can just push the drug-carrying microneedle to the instrument port, so that the drug-carrying component can be pushed to the acupuncture points around the eye smoothly and accurately. Among them, the pushing component is preferably made of ordinary hard plastic material.

[0042] In some preferred embodiments of the present invention, one end of the pushing component is connected to the middle of the flexible intermediate layer, and the other end is connected to the drug storage cavity; the drug-loaded microneedle is arranged on the side of the drug storage cavity away from the pushing component; the light-responsive material is distributed in the horizontal direction, and the drug-loaded component is distributed in the vertical direction. In this way, it can be ensured that when the pushing component is connected to the light-responsive material, the structure of the ultraviolet light response layer and the infrared light response layer can be avoided from being damaged, thereby affecting their performance. At the same time, when the light-responsive material is deformed, the drug-loaded component is pushed toward the human eye by the pushing component, and the drug-loaded microneedle injects the drug into the acupuncture points around the eye, thereby achieving the purpose of eye protection.

[0043] According to some preferred embodiments, the upper end of the drug storage cavity 15 is provided with a drug inlet 17. The drug storage cavity in the drug carrying assembly of the present invention is used to store drugs, and the upper end of the drug storage cavity is provided with a drug inlet to facilitate replenishing drugs at any time and realize repeated use.

[0044] According to some preferred embodiments, a cavity cover 18 is provided on the cavity 11. The present invention provides a cavity cover on the side close to the drug-loaded microneedle, and when the eye protector is not in use, the cavity cover is covered to protect the drug-loaded component in the cavity.

[0045] According to some preferred embodiments, a fixing component 19 for fixing the eye protector is provided on the cavity 11 .

[0046] According to some preferred embodiments, an infrared lamp 12 is disposed inside the cavity cover 18 for sterilizing and disinfecting the drug-carrying assembly.

[0047] According to some preferred embodiments, the thickness ratio of the ultraviolet light response layer 131 , the flexible intermediate layer 132 and the infrared light response layer 133 is 5:3 to 5:7.

[0048] According to some preferred embodiments, the ultraviolet response material used in the ultraviolet light response layer is obtained by chain extension reaction and curing of a mixed system containing polycaprolactone diol, glycerol, azobenzene-4,4'-dicarboxylic acid and a solvent under the action of an initiator and a catalyst; preferably, azobenzene-4,4'-dicarboxylic acid accounts for 3-7wt% in the ultraviolet light response layer. The present invention realizes light control in different ultraviolet bands by adjusting the content of azobenzene-4,4'-dicarboxylic acid. Within the above range, the larger the mass fraction of azobenzene-4,4'-dicarboxylic acid, the slower the deformation rate. Within the above range, the bending deformation time of 90° is 18-45s. The ultraviolet light absorption wavelength range of the ultraviolet response material is 330-400nm. When the mass of azobenzene-4,4'-dicarboxylic acid in the ultraviolet response material is 4%, under the irradiation of ultraviolet light with a wavelength of 365nm, the maximum bending angle is 90°, and the bending change time is completed within 40s.

[0049] According to some preferred embodiments, based on the total mass of polycaprolactone diol, glycerol, azobenzene-4,4'-dicarboxylic acid and initiator, polycaprolactone diol accounts for 75-80wt%, glycerol 2-3wt%, azobenzene-4,4'-dicarboxylic acid 3%-7%, and initiator 15-18%.

[0050] According to some preferred embodiments, the preparation method of the ultraviolet responsive material comprises: heating and melting polycaprolactone diol, cooling to 60°C, adding azobenzene-4,4′-dicarboxylic acid solution and a catalyst, and adding an initiator (isophorone diisocyanate) and glycerol in a nitrogen atmosphere, and obtaining a prepolymer through a chain extension reaction; defoaming and curing the prepolymer solution to obtain an ultraviolet responsive material. It should be noted that in order to better mix, the initiator and glycerol are added in the form of an initiator solution and a glycerol solution, and the catalyst is preferably an organic bismuth catalyst.

[0051] According to some specific embodiments, the preparation method of the ultraviolet responsive material includes: adding 5.86g of polycaprolactone diol to a three-necked flask and heating it to 120°C in a vacuum oven, keeping the three-necked flask containing the molten polycaprolactone diol isothermal for 4 hours, slowly cooling it to 60°C, and adding azobenzene-4,4′-dicarboxylic acid solution (0.22-0.53g of azobenzene-4,4′-dicarboxylic acid dissolved in 1.5mL of dimethylformamide (DMF)) and 0.2g of an organic bismuth catalyst (DY-20) at 60°C, and then placing the obtained mixed solution in a nitrogen atmosphere for 5 minutes, and within 20 minutes, slowly adding an initiator (isophorone diisocyanate) solution (obtained by dissolving 1.29-1.55g of isophorone diisocyanate in 5mL of DMF) to the three-necked flask, and finally adding a glycerol solution (obtained by dissolving 0.23g of glycerol in 5mL DMF is added into a three-necked culture bottle and stirred for 3 minutes to obtain a prepolymer through chain extension reaction. The prepolymer solution is placed in a planetary mixer and rotated at 3000 rpm for 3 minutes at room temperature (RT) to eliminate bubbles. The solution after the bubbles are eliminated is injected into a polytetrafluoroethylene (PTFE) mold and cured at 75-80°C for 17-19 hours to obtain a UV-responsive material.

[0052] According to some preferred embodiments, the infrared light response material used in the infrared light response layer is obtained by chain extension reaction and curing of a mixed system containing polycaprolactone diol, glycerol and carbon black under the action of an initiator and a catalyst; preferably, the carbon black in the infrared light response layer accounts for 0.1-1wt%. The present invention realizes light control in different infrared bands by adjusting the content of carbon black. The greater the mass fraction of carbon black in the above range, the faster the deformation rate. In the above range, the bending deformation time of 90° is 6.8-7.6s. The infrared light response material absorbs infrared light wavelengths in the range of 800nm ​​to 900nm. When the mass fraction of carbon black in the infrared response material is 0.2%, under the irradiation of infrared light with a wavelength of 808nm, it reaches maximum deformation at a maximum temperature of 38°C after irradiation for 30-35s, and the maximum bending angle is 90°.

[0053] According to some preferred embodiments, based on the total mass of polycaprolactone diol, glycerol, carbon black and initiator, polycaprolactone diol accounts for 75-78wt%, glycerol 3-3.6wt%, carbon black 0.1%-1%, and initiator 15-18%.

[0054] According to some preferred embodiments, the preparation method of the infrared light responsive material comprises: heating and melting polycaprolactone diol, cooling to 60°C, adding a carbon black dispersion and a catalyst, and adding an initiator (isophorone diisocyanate) and glycerol in a nitrogen atmosphere, and obtaining a first prepolymer solution through a chain extension reaction. The first prepolymer solution is defoamed and cured to obtain an infrared light responsive material. It should be noted that, in order to better mix, the initiator and glycerol are added in the form of an initiator solution and a glycerol solution, and the catalyst is preferably an organic bismuth catalyst.

[0055] According to some specific embodiments, the preparation method of the infrared light responsive material includes: adding 19.51g of polycaprolactone diol into a three-necked flask and heating it to 120°C in a vacuum oven, keeping the three-necked flask containing the molten polycaprolactone diol isothermal for 4 hours, slowly cooling it to 60°C, and adding a carbon black dispersion (obtained by dissolving 0.025-0.250g of carbon black in 1.5mL of dimethylformamide (DMF)) and 0.2g of an organic bismuth catalyst (DY-20) at 60°C, and then placing the obtained mixed solution in a nitrogen atmosphere for 5 minutes, and slowly adding an isophorone diisocyanate solution (obtained by dissolving 4.44g of isophorone diisocyanate in 5mL of DMF) to the three-necked flask within 20 minutes, and then adding a glycerol solution (obtained by dissolving 0.92g of glycerol in 5mL of DMF) to the three-necked flask and stirring for 3 minutes, and obtaining a second prepolymer solution through a chain extension reaction. The second prepolymer solution is placed in a planetary mixer and rotated at 3000 rpm for 3 minutes at room temperature (RT) to eliminate bubbles. The solution after the bubbles are eliminated is injected into a polytetrafluoroethylene (PTFE) mold and cured at 75 to 80° C. for 17 to 19 hours to obtain an infrared light responsive material.

[0056] According to some preferred embodiments, the temperature of the chain extension reaction is 58-63°C;

[0057] According to some preferred embodiments, the curing temperature is 75-80° C. and the curing time is 17-19 hours.

[0058] According to some preferred embodiments, the flexible material used for the flexible intermediate layer is one of porous silica gel and porous rubber.

[0059] According to some preferred embodiments, the preparation method of the light-responsive material 13 includes: pouring a first prepolymer solution into a mold, then placing a flexible material, and finally pouring a second prepolymer solution into the mold, and curing at 75 to 80° C. for 17 to 19 hours to obtain a light-responsive material with a three-layer structure. The flexible material has a porous structure, and during the composite process, the ultraviolet light-responsive material and the infrared light-responsive material will polymerize between the pores, so that it has strong interface adhesion.

[0060] According to some preferred embodiments, the drug-carrying component is a hydrogel material.

[0061] According to some preferred embodiments, the preparation method of the hydrogel material comprises: mixing glycine and an alkaline solution, adding an acryloyl chloride solution, reacting, removing the solvent, alkali dissolving, acid precipitation, and extracting to obtain a polymerized monomer;

[0062] The polymerizable monomer, tannic acid, nano-hydroxyapatite, iron salt and photoinitiator are mixed and subjected to a photocuring reaction to obtain a hydrogel material; preferably, the mass ratio of the iron salt to the tannic acid is 1:10-100.

[0063] The hydrogel material prepared by the above method can reach 42-60°C in a short time under infrared light irradiation. The limit stable temperature is determined by the mass ratio of iron salt to tannic acid (TA) in the microneedle material. Within the above range, the higher the iron salt content, the greater the limit stable temperature. This material is used in conjunction with the infrared lamp on the cavity cover to effectively sterilize and promote drug absorption. Before using the eye protector, inject the medicine into the drug-carrying component, cover the cavity cover, and then turn on the infrared lamp on the cavity cover for sterilization. After 2 minutes, turn off the infrared lamp, put on the eye protector, and fix the eye protector with a fixing component.

[0064] According to some specific embodiments, the preparation method of the hydrogel material includes: (1) adding 16 g of glycine to a sodium hydroxide solution (obtained by dissolving 18.1 g of sodium hydroxide in 100 mL of deionized water) and mixing evenly, standing and cooling, adding an acryloyl chloride solution (obtained by dissolving 19 mL of acryloyl chloride in 10 mL of anhydrous THF) in an ice water bath, and after the addition is complete, checking whether the pH of the reaction solution is alkaline to ensure that the HCl produced by the reaction is completely neutralized, continuing the reaction at room temperature for 4 to 5 hours, removing THF by rotary evaporation, and then using 4 mol / L NaOH aqueous solution and 6 mol / L hydrochloric acid for alkaline dissolution and acid precipitation, and finally extracting with ethyl acetate. After drying, a white solid product is obtained, which is the polymerized monomer.

[0065] (2) 1 g of polymer monomer was mixed with 2.35 mL of deionized water, and ultrasonic treatment was performed using a KQ-250E ultrasonic cleaner to uniformly mix the polymer monomer. 0.05 g of tannic acid, 0.07 g of nano-hydroxyapatite, ferric chloride hexahydrate (ferric chloride hexahydrate was added in an amount of 1:10 to 100 in the mass ratio of FeCl3 to tannic acid) and a photoinitiator (added in the form of a photoinitiator solution, 0.01 g of photoinitiator I2959 was dissolved in 0.01 mL of DMSO to obtain a photoinitiator solution) were added in sequence and stirred to mix well. After removing bubbles by ultrasonic treatment, the mixture was poured into a polytetrafluoroethylene mold, irradiated with an ultraviolet lamp for 10 min, and demolded to obtain a hydrogel material. It should be noted that when the hydrogel material is used to prepare the drug-carrying component, the mold corresponding to the drug-carrying component can be selected according to the specific structure of the drug-carrying component. In some preferred embodiments of the present invention, the specific parameters of the microneedle mold in the drug-carrying component are as follows: the needle shape is conical, the bottom diameter is 280 μm, and the length of the microneedle is 900 μm. It should be noted that the length of the microneedle of the present invention refers to the distance from the bottom of the microneedle to the tip of the microneedle.

[0066] According to some preferred embodiments, the photocuring reaction is performed by irradiating ultraviolet light for 10 minutes.

[0067] In order to more clearly illustrate the technical solutions and advantages of the present invention, the present invention is further described below in conjunction with the embodiments. The present invention does not specifically limit the sources of the reagents used in the embodiments, and they can be directly purchased or synthesized by themselves. It should be noted that the light-responsive material and drug-carrying component in the embodiments of the present invention are prepared by the following method.

[0068] The preparation method of the photoresponsive material comprises: (i) adding 5.86 g of polycaprolactone diol into a three-necked flask and heating it to 120° C. in a vacuum oven, keeping the three-necked flask containing the molten polycaprolactone diol isothermal for 4 hours, slowly cooling it to 60° C., and adding azobenzene-4,4′-dicarboxylic acid solution (obtained by dissolving 0.4 g of azobenzene-4,4′-dicarboxylic acid in 1.5 mL of dimethylformamide (DMF)) and 0.2 g of an organic bismuth catalyst (DY-20) at 60° C., then placing the obtained mixed solution in a nitrogen atmosphere for 5 minutes, and slowly adding an initiator solution (obtained by dissolving 1.29 to 1.55 g of isophorone diisocyanate in 5 mL of DMF) into the three-necked flask within 20 minutes, and finally adding a glycerol solution (obtained by dissolving 0.23 g of glycerol in 5 mL of DMF) into the three-necked culture flask, stirring it for 3 minutes, and obtaining a first prepolymer solution through a chain extension reaction. (ii) Preparation of infrared light responsive material: 19.51 g of polycaprolactone diol was added to a three-necked flask and heated to 120° C. in a vacuum oven. The three-necked flask containing the molten polycaprolactone diol was kept isothermal for 4 hours, then slowly cooled to 60° C., and a carbon black dispersion (0.2 g of carbon black was dissolved in 1.5 mL of dimethylformamide (DMF)) and 0.2 g of an organic bismuth catalyst (DY-20) were added at 60° C. The obtained mixed solution was then placed in a nitrogen atmosphere for 5 minutes, and an isophorone diisocyanate solution (4.44 g of isophorone diisocyanate was dissolved in 5 mL of DMF) was slowly added to the three-necked flask within 20 minutes. A glycerol solution (0.92 g of glycerol was dissolved in 5 mL of DMF) was then added to the three-necked flask and stirred for 3 minutes. After a chain extension reaction, a second prepolymer solution was obtained. The first prepolymer solution was placed in a planetary mixer and rotated at 3000 rpm for 3 minutes at room temperature to eliminate bubbles. The solution after the bubbles were eliminated was injected into a polytetrafluoroethylene (PTFE) mold, and then a flexible material (silicone) was placed. Finally, the second prepolymer solution was placed in a planetary mixer and rotated at 3000 rpm for 3 minutes at room temperature (RT) to eliminate bubbles. The solution after the bubbles were eliminated was injected into a polytetrafluoroethylene (PTFE) mold and cured at 80°C for 18 hours to obtain a photoresponsive material with a three-layer structure.

[0069] The preparation of the drug-carrying component comprises: (i) adding 16 g of glycine to a sodium hydroxide solution (obtained by dissolving 18.1 g of sodium hydroxide in 100 mL of deionized water) and mixing evenly, standing and cooling, adding an acryloyl chloride solution (obtained by mixing 19 mL of acryloyl chloride and 10 mL of anhydrous THF) in an ice water bath, and after the addition is complete, checking whether the pH of the reaction solution is alkaline to ensure that the HCl generated by the reaction is completely neutralized, continuing the reaction at room temperature for 4 to 5 hours, removing THF by rotary evaporation, and then performing alkaline dissolution and acid precipitation with a 4 mol / L NaOH aqueous solution and a 6 mol / L hydrochloric acid solution, and finally extracting with ethyl acetate. After drying, a white solid product is obtained, which is the polymerized monomer. (ii) 1 g of polymerized monomer was mixed with 2.35 mL of deionized water, and ultrasonic treatment was performed using a KQ-250E ultrasonic cleaner to uniformly mix the polymerized monomer, and 0.05 g of tannic acid, 0.07 g of nanohydroxyapatite, ferric chloride hexahydrate (ferric chloride hexahydrate was added in an amount of 1:25 in the mass ratio of FeCl3 to tannic acid) and a photoinitiator (added in the form of a photoinitiator solution, 0.01 g of photoinitiator I2959 was dissolved in 0.01 mL of DMSO to obtain a photoinitiator solution) were added in sequence and stirred to mix, and after removing bubbles by ultrasonic treatment, the mixture was poured into a polytetrafluoroethylene mold having the same structure as the drug-carrying component, and after irradiation with an ultraviolet lamp for 10 minutes, the drug-carrying component was demoulded to obtain the drug-carrying component. The specific parameters of the microneedle mold in the drug-carrying component are as follows: the needle shape is conical, the bottom diameter is 280 μm, and the length of the microneedle is 900 μm.

[0070] Example 1

[0071] The present invention provides an eye protection device, comprising a cavity 1 and a light driving component and a drug carrying component arranged inside the cavity 1;

[0072] The light-driven assembly includes an ultraviolet lamp 11 and an infrared lamp 12 which are arranged in a vertical direction inside the cavity and a light-responsive material 13 which is arranged between the ultraviolet lamp 11 and the infrared lamp 12;

[0073] The light response material 13 includes an ultraviolet light response layer 131 (made of ultraviolet light response material), a flexible middle layer 132 (silicone layer) and an infrared light response layer 133 (made of infrared light response material) which are arranged in sequence from top to bottom; the thickness ratio of the ultraviolet light response layer 131, the flexible middle layer 132 and the infrared light response layer 133 is 5:4:7; the ultraviolet light response layer 131 shrinks toward the light side under ultraviolet light irradiation, and then bends toward the backlight side; the infrared light response layer 133 shrinks toward the light side under infrared light irradiation, and then bends toward the backlight side;

[0074] The drug-carrying component is connected to the light-responsive material 13 through a pushing component 14; one end of the pushing component 14 connected to the light-responsive material 13 is lower than the end of the pushing component 14 connected to the drug-carrying component; the drug-carrying component includes a drug storage cavity 15 and a drug-carrying microneedle 16 arranged on the side wall of the drug storage cavity 15 and connected to the drug storage cavity 15; a drug inlet 17 is arranged at the upper end of the drug storage cavity 15; a cavity cover 18 is arranged on the cavity 1; a fixing component 19 for fixing the eye protector is arranged on the cavity 1; an infrared lamp 12 is arranged on the inner side of the cavity cover 18 for sterilizing and disinfecting the drug-carrying component.

[0075] Before using the eye protector, buckle the cavity cover, add medicine through the medicine inlet, turn on the infrared light on the cavity cover, sterilize and disinfect the drug-loaded microneedles, and turn it off after 2 minutes of irradiation; put on the eye protector, turn on the infrared light in the light-driven component, the light-responsive material bends and deforms upward, and the drug-loaded component is pushed toward the human eye through the pushing component, the drug-loaded microneedles penetrate, and the drug is accurately injected through penetration. After the medication is finished, turn off the infrared light in the light-driven component, turn on the ultraviolet light in the light-driven component, make the light-responsive material bend and deform downward, and drive the drug-loaded component away from the human eye through the pushing component.

[0076] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or make equivalent replacements for some of the technical features therein. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the spirit and scope of the technical solutions of the embodiments of the present invention.

Claims

1. An eye protection device based on light response, characterized in that: The eye protector comprises a cavity and a light-driven component and a drug-carrying component arranged inside the cavity; The optical drive assembly includes an ultraviolet lamp and an infrared lamp arranged in the cavity in an upper and lower relative manner and a light responsive material arranged between the ultraviolet lamp and the infrared lamp; The light-responsive material comprises an ultraviolet light-responsive layer, a flexible intermediate layer and an infrared light-responsive layer arranged in sequence from top to bottom; the ultraviolet light-responsive layer shrinks toward the light side under ultraviolet light irradiation and then bends toward the backlight side; The infrared light response layer shrinks toward the light side and then bends toward the backlight side when irradiated by infrared light; The drug-carrying component is connected to the light-responsive material via a pushing component; one end of the pushing component connected to the light-responsive material is lower than one end of the pushing component connected to the drug-carrying component; the drug-carrying component includes a drug storage cavity and a drug-carrying microneedle disposed on a side wall of the drug storage cavity and communicating with the drug storage cavity.

2. The eye protection device according to claim 1, characterized in that: The cavity is provided with a cavity cover; and / or The cavity is provided with a fixing component for fixing the eye protector.

3. The eye protection device according to claim 2, characterized in that: An infrared lamp is arranged inside the cavity cover to sterilize and disinfect the drug carrying component.

4. The eye protection device according to claim 1, characterized in that: The thickness ratio of the ultraviolet light response layer, the flexible intermediate layer and the infrared light response layer is 5:3 to 5:

7.

5. The eye protection device according to claim 1, characterized in that: The ultraviolet response material used in the ultraviolet response layer is obtained by chain extension reaction and curing of a mixed system including polycaprolactone diol, glycerol, azobenzene-4,4'-dicarboxylic acid and a solvent under the action of an initiator and a catalyst; preferably, azobenzene-4,4'-dicarboxylic acid accounts for 3-7wt% in the ultraviolet response layer.

6. The eye protection device according to claim 1, characterized in that: The infrared light response material used in the infrared light response layer is obtained by chain extension reaction and curing of a mixed system containing polycaprolactone diol, glycerol and carbon black under the action of an initiator and a catalyst; preferably, the carbon black in the infrared light response layer accounts for 0.1-1wt%.

7. The eye protection device according to claim 5 or 6, characterized in that: The temperature of the chain extension reaction is 58-63°C; and / or The curing temperature is 75-80° C. and the curing time is 17-19 hours.

8. The eye protection device according to claim 1, characterized in that: The flexible material used in the flexible intermediate layer is one of porous silica gel and porous rubber; and / or The drug-carrying component is a hydrogel material.

9. The eye protection device according to claim 8, characterized in that: The preparation method of the hydrogel material comprises: mixing glycine and an alkaline solution, adding an acryloyl chloride solution, reacting, removing the solvent, alkali dissolving, acid precipitation, and extracting to obtain a polymerized monomer; The polymerizable monomer, tannic acid, nano-hydroxyapatite, iron salt and photoinitiator are mixed and subjected to a photocuring reaction to obtain a hydrogel material; preferably, the mass ratio of the iron salt to the tannic acid is 1:10-100.

10. The eye protection device according to claim 9, characterized in that: The photocuring reaction is carried out by irradiating ultraviolet light for 9 to 11 minutes.

Images